Education
About Us
Working with TipRanks
Follow Us
Ocugen Inc (OCGN)
NASDAQ:OCGN
OCGN Stock Chart & Stats
$1.94
-$0.04(-4.99%)
At close: 4:00 PM EST
$1.94
-$0.04(-4.99%)
Day’s Range― - ―
52-Week Range$0.52 - $1.96
Previous CloseN/A
Volume1.89M
Average Volume (3M)4.50M
Market Cap
$636.10M
Enterprise Value$602.67M
Total Cash (Recent Filing)$32.56M
Total Debt (Recent Filing)$32.96M
Price to Earnings (P/E)―
Beta1.80
Next Earnings
Mar 04, 2026EPS Estimate
-0.06Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding327,888,370
10 Day Avg. Volume5,392,743
30 Day Avg. Volume4,499,764
Financial Highlights & Ratios
PEG Ratio0.17
Price to Book (P/B)7.36
Price to Sales (P/S)53.80
P/FCF Ratio-4.79
Enterprise Value/Market Cap0.95
Enterprise Value/Revenue112.23
Enterprise Value/Gross Profit112.23
Enterprise Value/Ebitda-10.48
Forecast
1Y Price Target
$7.67Price Target Upside295.36% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.24
Revenue Forecast (FY)$3.85M
Bulls Say, Bears Say
Bulls Say
Clinical EfficacyInterim mid-stage trial showed a statistically significant slowing of lesion growth compared with placebo, indicating potential to alter disease progression and strengthen regulatory arguments.
Financial RunwayCompleted equity financing provided additional capital that should extend the company's development runway through key clinical milestones, supporting ongoing program execution.
Safety ProfileReported clean ocular safety with no intraocular inflammation, vasculitis, or retinal detachment suggests lower inflammatory risk versus existing intravitreal treatments, which could improve physician and patient acceptance.
Bears Say
Execution And Intellectual Property RiskAnalyst warns that commercialization, clinical development, partnership dynamics, financial constraints, and intellectual property challenges could impede achievement of the price target and slow progress.
Market SentimentShares trading down to the offering price signals investor skepticism that could keep pressure on the stock until clearer commercial or clinical validation emerges.
Ocugen News
OCGN FAQ
What was Ocugen Inc’s price range in the past 12 months?
Ocugen Inc lowest stock price was $0.52 and its highest was $1.96 in the past 12 months.
What is Ocugen Inc’s market cap?
Ocugen Inc’s market cap is $636.10M.
When is Ocugen Inc’s upcoming earnings report date?
Ocugen Inc’s upcoming earnings report date is Mar 04, 2026 which is today.
How were Ocugen Inc’s earnings last quarter?
Currently, no data Available
Is Ocugen Inc overvalued?
According to Wall Street analysts Ocugen Inc’s price is currently Undervalued.
Does Ocugen Inc pay dividends?
Ocugen Inc does not currently pay dividends.
What is Ocugen Inc’s EPS estimate?
Ocugen Inc’s EPS estimate is -0.06.
How many shares outstanding does Ocugen Inc have?
Ocugen Inc has 327,888,370 shares outstanding.
What happened to Ocugen Inc’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Ocugen Inc?
Currently, no hedge funds are holding shares in OCGN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Ocugen Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$7.67 (295.36% Upside)
$7.67 (295.36% Upside)
Blogger Sentiment
Bullish
OCGN Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 4.2M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.0%
Last 30 Days ▼ 1.2%
Last 30 Days ▼ 1.2%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
198.00%
12-Months-Change
Fundamentals
Return on Equity
-289.93%
Trailing 12-Months
Asset Growth
-7.01%
Trailing 12-Months
Company Description
Ocugen Inc
Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, such as retinitis pigmentosa and leber congenital amaurosis; OCU410, gene therapy candidate for the treatment of dry age-related macular degeneration (AMD); and OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet AMD. Ocugen, Inc. has a strategic partnership with CanSino Biologics Inc. for gene therapy co-development and manufacturing; and Bharat Biotech for the commercialization of COVAXIN in the United States market. The company is headquartered in Malvern, Pennsylvania.
OCGN Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted significant advancements in gene therapy programs and strategic partnerships, alongside promising clinical data. However, the company faced increased operating expenses and a decline in cash position. Overall, the positive advancements and strategic positioning contribute to an optimistic outlook.View all OCGN earnings summariesOCGN Stock 12 Month Forecast
Average Price Target
$7.67
▲(295.36% Upside)
Technical Analysis
Sinovac Biotech
―
XOMA Royalty Corporation
―
ADC Therapeutics
―
Monte Rosa Therapeutics
―
AbSci
―
Ownership Overview
2.52% Insiders
5.16% Mutual Funds
0.76% Other Institutional Investors
85.92% Public Companies and
Individual Investors